OTCPK:NXSC.F

Stock Analysis Report

Executive Summary

Next Science Limited, a medical technology company, develops and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Risks

  • Next Science has significant price volatility in the past 3 months.
  • Next Science is not covered by any analysts.

Share Price & News

How has Next Science's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.0%

NXSC.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

NXSC.F

9.9%

US Medical Equipment

0.6%

US Market

No trading data on NXSC.F.

No trading data on NXSC.F.


Share holder returns

NXSC.FIndustryMarket
7 Day1.0%1.1%-0.6%
30 Day1.0%0.6%2.2%
90 Day-30.7%2.9%1.1%
1 Yearn/a10.8%9.9%2.9%0.6%
3 Yearn/a70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Next Science's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Next Science undervalued based on future cash flows and its price relative to the stock market?

14.71x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Next Science to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Next Science to establish if it is available at substantial discount.


Price Based on Earnings

Next Science is loss making, we can't compare its value to the US Medical Equipment industry average.

Next Science is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Next Science, we can't assess if its growth is good value.


Price Based on Value of Assets

Next Science is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Next Science expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Next Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Next Science performed over the past 5 years?

-78.5%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Next Science does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Next Science's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Next Science's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Next Science has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Next Science has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Next Science improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Next Science's financial position?


Financial Position Analysis

Next Science is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Next Science's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Next Science has no debt.

Next Science currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Next Science has no debt, it does not need to be covered by operating cash flow.

Next Science has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Next Science has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Next Science's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Next Science's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Next Science's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Next Science has not reported any payouts.

Unable to verify if Next Science's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Next Science has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Next Science's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Judith Mitchell 0

2.1yrs

Tenure

0

Ms. Judith Mitchell serves as Managing Director & CEO of Next Science Limited since August 2017 and serves as its a Director since October 20, 2017. Previously, Ms. Mitchell was President, DePuy Synthes As ...


Management Age and Tenure

1.3yrs

Average Tenure

The average tenure for the Next Science management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.5yrs

Average Tenure

The average tenure for the Next Science board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jacqueline Butler

    Chief Financial Officer

    • Tenure: 0yrs
  • Byron Darroch

    Executive Vice President of Partnerships

    • Tenure: 0yrs
  • Judith Mitchell

    MD, CEO & Director

    • Tenure: 2.1yrs
  • Matthew Myntti

    Founder & CTO

    • Tenure: 0yrs
  • Jon Swanson

    Chief Operating Officer

    • Tenure: 1.3yrs
  • Gillian Nairn

    Company Secretary

    • Tenure: 1.3yrs
  • Don Ayers

    Vice President of Sales & Marketing

    • Tenure: 0yrs

Board Members

  • George Savvides

    Independent Chairperson

    • Tenure: 1.2yrs
  • Mark Compton (58yo)

    Independent Non-Executive Director

    • Tenure: 0.9yrs
  • Bruce Hancox

    Non-Executive Director

    • Tenure: 7.4yrs
  • Judith Mitchell

    MD, CEO & Director

    • Tenure: 2.1yrs
  • Dan Spira

    Independent Non-Executive Director

    • Tenure: 1.9yrs
  • Aileen Stockburger

    Independent Non-Executive Director

    • Tenure: 0.9yrs

Company Information

Next Science Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Next Science Limited
  • Ticker: NXSC.F
  • Exchange: OTCPK
  • Founded: 2012
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$530.327m
  • Listing Market Cap: AU$359.057m
  • Shares outstanding: 179.16m
  • Website: https://www.nextscience.com

Location

  • Next Science Limited
  • Tower A
  • Level 19
  • Sydney
  • New South Wales
  • 2067
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NXSASX (Australian Securities Exchange)YesOrdinary SharesAUAUDApr 2019
NXSC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDApr 2019

Biography

Next Science Limited, a medical technology company, develops and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria. The company develops its ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 01:04
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.